Oral GLP‑1 Pill OK'd

The Food and Drug Administration approved Eli Lilly’s Foundayo, a once-daily obesity pill, on April 1, 2026. (fda.gov) Foundayo is the brand name for orforglipron, a glucagon-like peptide-1 drug that mimics a gut hormone tied to appetite and fullness. The approval covers adults with obesity, or adults who are overweight and have at least one weight-related medical problem, alongside diet and exercise. (accessdata.fda.gov) Lilly said the tablet can be taken at any time of day and does not require food or water restrictions. The company began taking prescriptions immediately after approval and said shipping started April 6 through LillyDirect, with broader pharmacy availability following. (lilly.com 1) (lilly.com 2) The label gives patients an oral alternative to injected obesity drugs such as Wegovy and Zepbound. That matters in a market where weekly shots have driven demand but also left some patients reluctant to start treatment or stay on it. (medicalnewstoday.com) (lilly.com) In Lilly’s 72-week ATTAIN-1 trial, adults without diabetes lost an average of 12.4% of body weight on the 36-milligram dose, or about 27.3 pounds, compared with placebo. The phase 3 study enrolled 3,127 patients and tested 6-milligram, 12-milligram, and 36-milligram daily doses. (nejm.org) The prescribing information carries a boxed warning about thyroid C-cell tumors based on findings in rodents. It also warns against use in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. (pi.lilly.com) Common side effects listed in the label include nausea, vomiting, diarrhea, constipation, indigestion, and stomach pain. The label also warns about pancreatitis, gallbladder problems, low blood sugar when used with insulin or insulin secretagogues, acute kidney injury, diabetic retinopathy complications in patients with type 2 diabetes, and suicidal behavior or thinking. (pi.lilly.com) The approval also arrived unusually fast. The FDA said it cleared Foundayo 50 days after filing, 294 days before the original Prescription Drug User Fee Act target date of January 20, 2027, under the agency’s Commissioner’s National Priority Voucher pilot program. (fda.gov) Lilly said Foundayo starts at $25 a month for commercially insured patients and $149 a month for self-pay through LillyDirect. The pill opens the obesity market to patients who want the same hormone pathway in a bottle instead of a pen. (lilly.com)